Oral quinine for the treatment of uncomplicated malaria

BMJ (Online)

Volumn 339, Issue 7715, 2009, Pages 248-

  Reyburn, Hugh ^a   Mtove, George ^b   Hendriksen, Ilse ^c   Von Seidlein, Lorenz ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Bombo Hospital   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; CLINDAMYCIN; QUININE; TETRACYCLINE;

AFRICA; DISEASE SEVERITY; DRUG QUALITY; DRUG SAFETY; EDITORIAL; HUMAN; MALARIA; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; UGANDA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; HUMANS; MALARIA; PLASMODIUM FALCIPARUM; QUININE;

EID: 68149089861     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b2763     Document Type: Editorial

References (11)

1. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363:9-17.[CrossRef][Web of Science][Medline] . 2. Omari AA, Gamble C, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2006;(2):CD005965. (Pubitemid 38076919)
2. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangeni F, Kamya MR, Dorsey G, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009;338:b2763.
3. Kangwana BB, Njogu J, Wasunna B, Kedenge SV, Memusi DN, Goodman CA, et al. Malaria drug shortages in Kenya: a major failure to provide access to effective treatment. Am J Trop Med Hyg 2009;80:737-738[Abstract/Free Full Text]
4. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-725[CrossRef][Web of Science][Medline] (Pubitemid 41207233)
5. Ndong JM, Atteke C, Aubouy A, Bakary M, Lebibi J, Deloron P. In vitro activity of chloroquine, quinine, mefloquine and halofantrine against Gabonese isolates of Plasmodium falciparum. Trop Med Int Health 2003;8:25-29[CrossRef] [Web of Science][Medline]
6. Quashie NB, Duah NO, Abuaku B, Koram KA. The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Ann Trop Med Parasitol 2007;101:391-398[CrossRef][Web of Science] [Medline] (Pubitemid 47488127)
7. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006;44:2404-2408[Abstract/Free Full Text] (Pubitemid 44092404)
8. Tinto H, Rwagacondo C, Karema C, Mupfasoni D, Vandoren W, Rusanganwa E, et al. In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg 2006;100:509-514 [CrossRef][Web of Science][Medline]
9. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995;332:1399-1404[Abstract/Free Full Text]
10. WHO. Guidelines for the treatment of malaria. 2006, http://apps.who.int/ malaria /docs/TreatmentGuidelines2006.pdf.
11. WHO. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiol Rec 2007;82:360.[Medline]